Stock Screener App

무료 -

설치하다

0.9535

1.44% 0.0135

Allarity Therapeutics Inc (ALLR)

개요 뉴스 가격 이력 Financials 토론 예측 주식 분할

Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Connect - Markets Insider

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Shareholders to Reach Out - Markets Insider

Allarity Therapeutics Inc (ALLR) is looking forward to a strong quarter - SETE News

Can Allarity Therapeutics Inc (ALLR) meet market expectations this quarter? - US Post News

Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation - Markets Insider

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Investors to Learn More About the Investigation - Markets Insider

Allarity Therapeutics advances ovarian cancer drug trial - MSN

Allarity Therapeutics (NASDAQ:ALLR) and Xilio Therapeutics (NASDAQ:XLO) Financial Contrast - Defense World

Allarity Therapeutics Inc (NASDAQ: ALLR) Gain Of 13.46% Compared To 52-Week Low; YTD Fall -11.11% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect - Markets Insider

Allarity Therapeutics Announces Expansion of Phase 2 - GlobeNewswire

Breakthrough Ovarian Cancer Drug Shows 14-Month Durability: Allarity Advances Clinical Trial - StockTitan

Allarity Therapeutics Inc’s Shares Reel: -24.64% Quarterly Revenue Decline Amid 4.68M Market Cap - The InvestChronicle

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Reach Out - Markets Insider

ALLR’s earnings forecast for the current quarter - US Post News

Ratios Reveal: Breaking Down Allarity Therapeutics Inc (ALLR)’s Financial Health - The Dwinnex

Allarity Therapeutics Reaches Settlement in Principle with SEC - Defense World

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect - Markets Insider

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC - GlobeNewswire

Allarity's Stenoparib Shows 14-Month Patient Response as Company Nears SEC Resolution - StockTitan

Allarity Therapeutics Reaches Settlement Agreement in Principle with SEC Regarding Prior Disclosures - Nasdaq

2025-01-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect | NDAQ:ALLR | Press Release - Stockhouse Publishing

ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

When Does Allarity Therapeutics Inc (ALLR) Become A Good Investment? - Marketing Sentinel

2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire

No Stopping Allarity Therapeutics Inc (NASDAQ: ALLR)’s Stock Surged? - Stocks Register

2025-01-19 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing

2025-01-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out | NDAQ:ALLR | Press Release - Stockhouse Publishing

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire

2025-01-08 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation - AccessWire

2025-01-02 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire

2024-12-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing

Cancer, GI-focused Onconic shares take off after ₩20B IPO - BioWorld Online

ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online

ALLARITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws - The Eastern Progress Online

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - Kilgore News Herald

ALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online

Allarity Therapeutics stock hits 52-week low at $1.03 - Investing.com

Allarity Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com UK

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming DeadlinesALLR - Longview News-Journal

RPRX

$33.42

0.27%

INSM

$81.06

3.05%

UTHR

$361.10

1.70%

SMMT

$22.12

4.08%

ONC

$255.37

4.57%

BNTX

$120.01

1.81%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개